Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 28

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 28
---
 of the Exchange Warrants in light of your own particular situation and with respect to any tax consequences arising under the laws of any state, local, foreign or other taxing jurisdiction. See “Material U.S. Federal Income Tax Considerations of the Notes and Warrants” in this prospectus. Resale of Common Stock by the Selling Stockholders

| Shares of Common Stock offered by the Selling Securityholders | Up to 1,703,946 shares of our Common Stock consisting of (i) 275,000 September 2025 Warrant Shares and (ii) 1,428,946 November 2025 Warrant Shares. |

| Use of proceeds | We will not receive any proceeds from the sale of shares of Common Stock by the Selling Stockholders, except with respect to amounts received by us upon the exercise of the September 2025 Warrants and the November 2025 Warrants for cash. |

| Market for our Common Stock | Our Common Stock is listed on the Nasdaq Capital Market under the symbol “SCLX.” |

| Risk Factors | See “Risk Factors” beginning on page 21 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in the securities being offered by this prospectus. |

| (1) | The number of shares of Common Stock outstanding assumes that an aggregate of 8,491,267 shares are           
 outstanding as of December 5, 2025, and excludes up to 12,517,343 shares issuable pursuant to the following: |

| • |     | 18,657 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2017                                          
 Scilex Pharmaceuticals Inc. Equity Incentive Plan (the “Scilex Pharma 2017 Plan”) with a weighted average exercise price of $27.03 per share; |

| • |     | 427,922 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2019                        
 Stock Option Plan of Scilex, Inc. (the “2019 Stock Option Plan”) with a weighted average exercise price of $60.55 per share; |

| • |     | 1,060,139 shares of Common Stock issuable upon the exercise of stock options outstanding under the Scilex                              
 Holding Company 2022 Equity Incentive Plan (the “Equity Incentive Plan”), with a weighted average exercise price of $114.04 per share; |

| • |